Alejandro Cuellar-Bravo

Guadalajara, JAL 44340, Mexico

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Discovery and Development of a TGFβ3/IL-13 Plasma Risk Score for Preoperative Discrimination of Benign and Malignant Ovarian Adnexal Masses.

Discovery and Development of a TGFβ3/IL-13 Plasma Risk Score for Preoperative Discrimination of Benign and Malignant Ovarian Adnexal Masses.

Journal: Diagnostics (Basel, Switzerland)

Published: May 22, 2026

Pentoxifylline in patients with COVID-19 and with liver cirrhosis or metabolic dysfunction-associated steatotic liver disease: Emerging insights.

Pentoxifylline in patients with COVID-19 and with liver cirrhosis or metabolic dysfunction-associated steatotic liver disease: Emerging insights.

Journal: Biomedical reports

Published: October 23, 2025

Pentoxifylline Enhances the Effects of Doxorubicin and Bleomycin on Apoptosis, Caspase Activity, and Cell Cycle While Reducing Proliferation and Senescence in Hodgkin's Disease Cell Line.

Pentoxifylline Enhances the Effects of Doxorubicin and Bleomycin on Apoptosis, Caspase Activity, and Cell Cycle While Reducing Proliferation and Senescence in Hodgkin's Disease Cell Line.

Journal: Current issues in molecular biology

Published: May 31, 2025

Chemotherapy with a molecular rational basis, pentoxifylline as a promising antitumor drug.

Chemotherapy with a molecular rational basis, pentoxifylline as a promising antitumor drug.

Journal: Annals of medicine and surgery (2012)

Published: November 11, 2024

Improvement of Docetaxel Efficacy through Simultaneous Blockade of Transcription Factors NF-κB and STAT-3 Using Pentoxifylline and Stattic in Prostate Cancer Cells.

Improvement of Docetaxel Efficacy through Simultaneous Blockade of Transcription Factors NF-κB and STAT-3 Using Pentoxifylline and Stattic in Prostate Cancer Cells.

Journal: Current issues in molecular biology

Published: August 07, 2024

Prolonged use of pentoxifylline increases the life expectancy of patients with compensated cirrhosis: A 20‑year retrospective study.

Prolonged use of pentoxifylline increases the life expectancy of patients with compensated cirrhosis: A 20‑year retrospective study.

Journal: Biomedical reports

Published: April 18, 2024

Very early remission and increased apoptosis with the use of Pentoxifylline in children with acute lymphoblastic leukemia.

Very early remission and increased apoptosis with the use of Pentoxifylline in children with acute lymphoblastic leukemia.

Journal: Frontiers in oncology

Published: March 15, 2024

Ulcerative colitis and pyoderma gangrenosum refractory to treatment successfully managed with pentoxifylline: a case report.

Ulcerative colitis and pyoderma gangrenosum refractory to treatment successfully managed with pentoxifylline: a case report.

Journal: Annals of medicine and surgery (2012)

Published: August 17, 2023

Expression of ornithine decarboxylase in peripheral blood mononuclear cells from patients with pancreatic adenocarcinoma: A preliminary report.

Expression of ornithine decarboxylase in peripheral blood mononuclear cells from patients with pancreatic adenocarcinoma: A preliminary report.

Journal: Biomedical reports

Published: May 31, 2023

Pentoxifylline Inhibits TNF-α/TGF-β1-Induced Epithelial-Mesenchymal Transition via Suppressing the NF-κB Pathway and SERPINE1 Expression in CaSki Cells.

Pentoxifylline Inhibits TNF-α/TGF-β1-Induced Epithelial-Mesenchymal Transition via Suppressing the NF-κB Pathway and SERPINE1 Expression in CaSki Cells.

Journal: International journal of molecular sciences

Published: May 26, 2023

The role of miRNA in prostate cancer diagnosis, prognosis and treatment response: a narrative review.

The role of miRNA in prostate cancer diagnosis, prognosis and treatment response: a narrative review.

Journal: Future oncology (London, England)

Published: January 27, 2023

Dual STAT‑3 and IL‑6R inhibition with stattic and tocilizumab decreases migration, invasion and proliferation of prostate cancer cells by targeting the IL‑6/IL‑6R/STAT‑3 axis.

Dual STAT‑3 and IL‑6R inhibition with stattic and tocilizumab decreases migration, invasion and proliferation of prostate cancer cells by targeting the IL‑6/IL‑6R/STAT‑3 axis.

Journal: Oncology reports

Published: January 21, 2022

Showing 1-12 of 44

Last Updated: 09/26/2026